In Japan, antiretroviral agents are approved on the basis of non-clinical...
In Japan, antiretroviral agents are approved on the basis of non-clinical and clinical data reported from overseas. However, evidence suggesting...
23 Jan, 2019
A recent retrospective analysis comparing the clinical and treatment outcomes in HIV-infected patients with motor neuron syndrome (MNS) and HIV-...
11 Jan, 2019
A recent analysis investigating the association between efavirenz (EFV) use during conception or first trimester (T1) of pregnancy and the...
09 Jan, 2019
Elbasvir/grazoprevir is a once-daily fixed-dose combination therapy for the treatment of chronic HCV infection, including HCV/HIV co-infection. ...
08 Jan, 2019
This trial compares the safety and efficacy of TAF vs TDF co-formulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of...
This study compared the enhanced and standard antimicrobial prophylaxis treatment in patients with advanced HIV disease.
Pre-exposure Prophylaxis Initiative (iPrEx) trial was a randomized, double-blind, placebo controlled trial aimed to evaluate the safety and efficacy...
The Partners PrEP Study is a double-blind, placebo-controlled, phase III clinical trial aimed to assess the safety and efficacy of oral PrEP for the...
Tuberculosis (TB) is the most common presenting illness and is one of the leading causes of death in people with HIV, particularly in low-income...
This publication features commonly asked questions by HIV patients regarding HIV therapy, drug side-effects, Do’s and Don’ts while on HIV treatment...
This publication features common questions which arise in HIV patients mind regarding HIV, diagnosis, transmission, treatment and drug side effects...
This slide set covers the epidemiology, disease progression and management of HIV-HCV coinfection in the era of directly acting antivirals available...
PrEP is the use of an antiretroviral medication by HIV-negative individuals to prevent them from acquiring HIV. These slides give an overview on the...
Post-exposure prophylaxis (PEP) is the method of preventing exposures of HIV to blood and body fluids and it is considered to be the most important...
HIV is the strongest risk factor for developing tuberculosis (TB) disease in those with latent or new Mycobacterium tuberculosis infection....